Biosimilars Market, Europe, Forecast to 2025

Biosimilars Market, Europe, Forecast to 2025

A Growing Number of Incentive Policies to Propel Growth in the Next 5–7 Years, with Oncology as the Fastest Adopter

RELEASE DATE
29-Mar-2017
REGION
Europe
Research Code: MCAA-01-00-00-00
SKU: HC02784-EU-MT_19846
$4,950.00
In stock
SKU
HC02784-EU-MT_19846
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU.

Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years.

The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issues to determine the strategic imperatives for success and growth in this market. Moreover, it includes an in-depth analysis of the biosimilar value chain and the payer and regulatory environment. By assessing the impact of trends, disruptive technologies, and new business models, the study arrives at key visioning scenarios for the biosimilars market in Europe. These will help market participants make strategic decisions, stay ahead of their competitors, and gain a significant share in the market. The study also sheds light on strategic partnerships among companies in the European biosimilars market.

Highlights of the report include:
•     Growth Opportunities and Challenges
•     Supply Market Dynamics
•     Payer and Regulatory Environment Analysis
•     Strategic Imperatives for Success and Growth–The Six Tactical Issues
•     Visioning Scenarios for the Biosimilars Market
•     Business Model Essentials
•     A Macro Overview of the Biosimilars Market

Table of Contents

Pharma/Biotech Market—Emerging Trends

Market Snapshot—Biosimilars

Revenue Forecast

Revenue Forecast by Region

Percent Revenue Forecast by Region

Biosimilars Ecosystem—Industry Convergence Map

Ecosystem Partnerships—An Opportunity

Changing Market Scenario—Disruptive Trends

Patent Expiries

Key Regions

Technology Innovation

Global Biosimilars Industry—Six Big Market Themes

Market Overview

Key Challenges in the Biosimilars Market

Market Segmentation by Therapeutic Areas

Trends in the Global Biosimilars Market

Global Biosimilar Patenting Trends

Biosimilars Adoption—Key Determinants

Physician Adoption of Biosimilars—Major Determinants

Drivers and Restraints

Impact Mapping of Drivers and Restraints

Percent Revenue Forecast by Region

Revenue Forecast

Revenue Forecast by Molecule Type

Snapshot—EU Biosimilars Market

Opportunity Heat Map—European Biosimilars Market.

Top-selling Biotech Drugs

Growth Opportunities in Oncology

Trastuzumab Biosimilars Adoption Rate

Trastuzumab Biosimilars Patient Population

Trastuzumab Biosimilars

Bevacizumab Biosimilars

Top-selling Biotech Drugs

Growth Opportunities in Diabetes

Insulin Glargine Biosimilars

Top-selling Biotech drugs

Growth Opportunities in Rheumatoid Arthritis

Etanercept Biosimilars

Infliximab Biosimilars

Adalimumab Biosimilars

Challenge 1—Interchangeability

Challenge 2—Innovation in Biologics and Biobetters

Future of Biosimilars in Europe

Competitive Landscape Analysis

Market Analysis—Europe

Regional Hot Spots—EU5 Perspective

Country Attractiveness

Biosimilar Uptake in Scandinavia—A Case Study

Key Companies to Watch

Merger, Acquisition, and Partnership Assessment

Biosimilars under Review by EMA

Payer Environment

Regulatory Environment

Impact of Policies—An EU5 Perspective

Development Process and Technical Requirements

Business Models to Mitigate Concerns over Cost

Strategic Imperatives for Success and Growth

Strategies for Innovators—Case Studies

Strategies for Foreign Participants in the EU

Visioning Scenarios for the Biosimilars Market

Business Model Essentials

Competitive Keys for Success in the Biosimilars Market

Legal Disclaimer

Global Regulatory Landscape

Impact of Regulations in the Biosimilars Market

Biosimilars are Not Generics—A Comparison of Generics, Biologics, and Biosimilars

Biologics and Biosimilars—Differences in Manufacturing Processes

Development Process and Technical Requirements for Biosimilars

Timeline for the Development of a Biosimilar Medicine

Value Chain Analysis—Development of a Biosimilar

Market Evolution of Biosimilars, 2015

Comparing the Players—Big Pharma (Innovators), Biotech Firms, and Generic Manufactures

List of Biosimilars Approved in Europe

List of Biosimilars under Review by EMA

List of Figures
  • 1. Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004–2021
  • 2. Total Biosimilars Market: Key Trends, Global, 2016
  • 3. Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000–2030
  • 4. Total Biosimilars Market: Key Regions, Global, 2016
  • 5. Total Biosimilars Market: Market Trends, Europe, 2016
  • 6. Total Biosimilars Market: Key Trends and Highlights, Global, 2016
  • 7. Total Biosimilars Market: Biosimilars Adoption, Key Determinants, Global, 2017–2025
  • 8. Total Biosimilars Market: Biologic versus Biosimilar, Global, 2015
  • 9. Total Biosimilars Market: Key Market Drivers and Restraints, Europe, 2017–2025
  • 10. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
  • 11. Total Biosimilars Market: Biosimilars Snapshot, Europe, 2017–2025
  • 12. Total Biosimilars Market: Opportunity Heat Map, Europe, 2017–2025
  • 13. Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
  • 14. Oncology Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
  • 15. Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014–2025
  • 16. Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025
  • 17. Oncology Therapeutic Segment: Herceptin® Price and Biosimilars Discount, Europe, 2014–2025
  • 18. Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014–2025
  • 19. Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025
  • 20. Oncology Therapeutic Segment: Avastin® Price and Biosimilars Discount, Europe, 2014–2025
  • 21. Diabetes Therapeutic Segment: Top Selling Biotech Drugs, Europe, 2015
  • 22. Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
  • 23. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014–2025
  • 24. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025
  • 25. Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014–2025
  • 26. Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
  • 27. Rheumatoid Arthritis Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
  • 28. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014–2025
  • 29. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025
  • 30. Rheumatoid Arthritis Therapeutic Segment: Enbrel® Price and Biosimilars Discount, Europe, 2014–2025
  • 31. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014–2025
  • 32. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025
  • 33. Rheumatoid Arthritis Therapeutic Segment: Remicade® Price and Biosimilars Discount, Europe, 2014–2025
  • 34. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014–2025
  • 35. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025
  • 36. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
  • 37. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
  • 38. Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015–16
  • 39. Total Biosimilars Market: Regulatory Approval Pathway in Europe, 2016
  • 40. Total Biosimilars Market: Impact of Country-level Policies, Europe, 2016
  • 41. Total Biosimilars Market: Strategies for Foreign Participants, Europe, 2016
  • 42. Total Biosimilars Market: Assessing the Future Impact of Trends, Disruptive Technologies, and New Business Models, Europe, 2016–2025
  • 43. Total Biosimilars Market: Comparison of Generics, Biologics, and Biosimilars, Europe, 2016
  • 44. Total Biosimilars Market: Key Trends and Highlights, Global, 2015–2016
  • 45. Total Biosimilars Market: Differences in the Manufacturing Processes of Biologics and Biosimilars, Global, 2015–2016
  • 46. Total Biosimilars Market: Data Requirements for Biosimilar Development, Global, 2016
  • 47. Total European Biosimilars Market: Timeline of Key Events, Global, 2015
  • 48. Total Biosimilars Market: A Comparison of Market Players, Europe, 2016
  • 49. Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016
  • 50. Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016
List of Charts
  • 1. Total Biosimilar Market: Percent Revenue Forecast by Region, Global, 2016 and 2025
  • 2. Total Biosimilars Market: Revenue Forecast, Global, 2015–2025
  • 3. Total Biosimilars Market: Revenue Forecast by Region, Global, 2015–2025
  • 4. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
  • 5. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
  • 6. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
  • 7. Total Biosimilars Market: Revenue Forecast, Europe, 2015–2025
  • 8. Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015–2025
  • 9. Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015–2025
  • 10. Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015–2025
  • 11. Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015–2025
  • 12. Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015–2025
  • 13. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015–2025
  • 14. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015–2025
  • 15. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015–2025
  • 16. Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015–2025
  • 17. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015–2025
  • 18. Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015–2025
  • 19. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015–2025
  • 20. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015–2025
  • 21. Total Biosimilars Market: Percent of Sales, Europe, 2015
  • 22. Total Biosimilars Market: Regional Growth Rates, Global, 2015
  • 23. Total Biosimilars Market: Adoption of Biosimilar Infliximab as a % of the Total Infliximab Market, Scandinavia, 2016
  • 24. Total Biosimilars Market: Timeline for the Development of a Biosimilar Medicine, Global, 2015–2016
Related Research
Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020. The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU. Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years. The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issu
More Information
No Index No
Podcast No
Table of Contents | Executive Dashboard~ || Pharma/Biotech Market—Emerging Trends~ || Market Snapshot—Biosimilars~ || Revenue Forecast~ || Revenue Forecast by Region~ || Percent Revenue Forecast by Region~ || Biosimilars Ecosystem—Industry Convergence Map~ || Ecosystem Partnerships—An Opportunity~ || Changing Market Scenario—Disruptive Trends~ || Patent Expiries~ || Key Regions~ || Technology Innovation~ || Global Biosimilars Industry—Six Big Market Themes~ | Growth Environment~ || Market Overview~ || Key Challenges in the Biosimilars Market~ || Market Segmentation by Therapeutic Areas~ || Trends in the Global Biosimilars Market~ || Global Biosimilar Patenting Trends~ || Biosimilars Adoption—Key Determinants~ || Physician Adoption of Biosimilars—Major Determinants~ | Drivers and Restraints—Total European Biosimilars Market~ || Drivers and Restraints~ || Impact Mapping of Drivers and Restraints~ | Growth Opportunity and Market Forecast—Total European Biosimilars Market~ || Percent Revenue Forecast by Region~ || Revenue Forecast~ || Revenue Forecast by Molecule Type~ || Snapshot—EU Biosimilars Market~ || Opportunity Heat Map—European Biosimilars Market.~ | Growth Opportunity and Market Forecast of Key Biosimilars—Oncology~ || Top-selling Biotech Drugs~ || Growth Opportunities in Oncology~ || Trastuzumab Biosimilars Adoption Rate~ || Trastuzumab Biosimilars Patient Population~ || Trastuzumab Biosimilars~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Bevacizumab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Growth Opportunity and Market Forecast of Key Biosimilars—Diabetes~ || Top-selling Biotech Drugs~ || Growth Opportunities in Diabetes~ || Insulin Glargine Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Growth Opportunity and Market Forecast of Key Biosimilars—Rheumatoid Arthritis~ || Top-selling Biotech drugs~ || Growth Opportunities in Rheumatoid Arthritis~ || Etanercept Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Infliximab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Adalimumab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Market Challenges—Biosimilars~ || Challenge 1—Interchangeability~ || Challenge 2—Innovation in Biologics and Biobetters~ | Supply Market Dynamics—Europe~ || Future of Biosimilars in Europe ~ || Competitive Landscape Analysis~ || Market Analysis—Europe~ || Regional Hot Spots—EU5 Perspective~ || Country Attractiveness~ || Biosimilar Uptake in Scandinavia—A Case Study~ || Key Companies to Watch~ || Merger, Acquisition, and Partnership Assessment~ || Biosimilars under Review by EMA~ | Strategic Imperatives and Critical Success Factors for Europe~ || Payer Environment~ || Regulatory Environment~ || Impact of Policies—An EU5 Perspective~ || Development Process and Technical Requirements~ || Business Models to Mitigate Concerns over Cost~ || Strategic Imperatives for Success and Growth~ || Strategies for Innovators—Case Studies~ || Strategies for Foreign Participants in the EU~ | Conclusion~ || Visioning Scenarios for the Biosimilars Market~ || Business Model Essentials~ || Competitive Keys for Success in the Biosimilars Market~ || Legal Disclaimer~ | Appendix~ || Global Regulatory Landscape~ || Impact of Regulations in the Biosimilars Market~ | Introduction to Biosimilars~ || Biosimilars are Not Generics—A Comparison of Generics, Biologics, and Biosimilars~ || Biologics and Biosimilars—Differences in Manufacturing Processes~ || Development Process and Technical Requirements for Biosimilars~ || Timeline for the Development of a Biosimilar Medicine~ || Value Chain Analysis—Development of a Biosimilar~ || Market Evolution of Biosimilars, 2015~ || Comparing the Players—Big Pharma (Innovators), Biotech Firms, and Generic Manufactures~ || List of Biosimilars Approved in Europe~ || List of Biosimilars under Review by EMA~
List of Charts and Figures 1. Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004–2021~ 2. Total Biosimilars Market: Key Trends, Global, 2016~ 3. Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000–2030~ 4. Total Biosimilars Market: Key Regions, Global, 2016~ 5. Total Biosimilars Market: Market Trends, Europe, 2016~ 6. Total Biosimilars Market: Key Trends and Highlights, Global, 2016~ 7. Total Biosimilars Market: Biosimilars Adoption, Key Determinants, Global, 2017–2025~ 8. Total Biosimilars Market: Biologic versus Biosimilar, Global, 2015~ 9. Total Biosimilars Market: Key Market Drivers and Restraints, Europe, 2017–2025~ 10. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025~ 11. Total Biosimilars Market: Biosimilars Snapshot, Europe, 2017–2025~ 12. Total Biosimilars Market: Opportunity Heat Map, Europe, 2017–2025~ 13. Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015 ~ 14. Oncology Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 15. Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014–2025~ 16. Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025~ 17. Oncology Therapeutic Segment: Herceptin® Price and Biosimilars Discount, Europe, 2014–2025~ 18. Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014–2025~ 19. Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025~ 20. Oncology Therapeutic Segment: Avastin® Price and Biosimilars Discount, Europe, 2014–2025~ 21. Diabetes Therapeutic Segment: Top Selling Biotech Drugs, Europe, 2015 ~ 22. Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 23. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014–2025~ 24. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025~ 25. Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014–2025~ 26. Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015 ~ 27. Rheumatoid Arthritis Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 28. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014–2025~ 29. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025~ 30. Rheumatoid Arthritis Therapeutic Segment: Enbrel® Price and Biosimilars Discount, Europe, 2014–2025~ 31. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014–2025~ 32. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025~ 33. Rheumatoid Arthritis Therapeutic Segment: Remicade® Price and Biosimilars Discount, Europe, 2014–2025~ 34. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014–2025~ 35. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025~ 36. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16~ 37. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16~ 38. Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015–16~ 39. Total Biosimilars Market: Regulatory Approval Pathway in Europe, 2016 ~ 40. Total Biosimilars Market: Impact of Country-level Policies, Europe, 2016~ 41. Total Biosimilars Market: Strategies for Foreign Participants, Europe, 2016~ 42. Total Biosimilars Market: Assessing the Future Impact of Trends, Disruptive Technologies, and New Business Models, Europe, 2016–2025~ 43. Total Biosimilars Market: Comparison of Generics, Biologics, and Biosimilars, Europe, 2016~ 44. Total Biosimilars Market: Key Trends and Highlights, Global, 2015–2016~ 45. Total Biosimilars Market: Differences in the Manufacturing Processes of Biologics and Biosimilars, Global, 2015–2016~ 46. Total Biosimilars Market: Data Requirements for Biosimilar Development, Global, 2016~ 47. Total European Biosimilars Market: Timeline of Key Events, Global, 2015~ 48. Total Biosimilars Market: A Comparison of Market Players, Europe, 2016~ 49. Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016~ 50. Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016~| 1. Total Biosimilar Market: Percent Revenue Forecast by Region, Global, 2016 and 2025~ 2. Total Biosimilars Market: Revenue Forecast, Global, 2015–2025~ 3. Total Biosimilars Market: Revenue Forecast by Region, Global, 2015–2025~ 4. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025~ 5. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025~ 6. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025~ 7. Total Biosimilars Market: Revenue Forecast, Europe, 2015–2025~ 8. Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015–2025~ 9. Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015–2025~ 10. Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015–2025~ 11. Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 12. Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015–2025~ 13. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015–2025~ 14. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015–2025~ 15. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015–2025~ 16. Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015–2025~ 17. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 18. Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015–2025~ 19. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 20. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015–2025~ 21. Total Biosimilars Market: Percent of Sales, Europe, 2015~ 22. Total Biosimilars Market: Regional Growth Rates, Global, 2015~ 23. Total Biosimilars Market: Adoption of Biosimilar Infliximab as a % of the Total Infliximab Market, Scandinavia, 2016~ 24. Total Biosimilars Market: Timeline for the Development of a Biosimilar Medicine, Global, 2015–2016~
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Saravanan Thangaraj
Industries Healthcare
WIP Number MCAA-01-00-00-00
Is Prebook No